and extremities since two months associated with fever.
INTRODUCTION
S weet's syndrome is characterized by painful erythematous plaques on the skin associated with fever, leukocytosis, and neutrophilia. [1] It is very rare in children, fewer than 80 cases are reported in the literature. [2] Marshall's syndrome is also rare pediatric skin disease characterized by acquired, localized, neutrophilic dermatosis (Sweet's disease) followed by loss of elastic tissue in the dermis and cutis laxa. [3] Sweet's syndrome shows a rapid and excellent response to systemic steroids, so the progression of Sweet's syndrome and development of new cutis laxa lesions can be halted.
CASE REPORT
A 4-year-old boy presented with a history of red raised painful skin lesions on the abdomen, chest, lesions showed an illusion of vesiculations. The majority of lesions coalesced to form large polycyclic configuration, distributed over the abdomen, gluteal area, and extremities [ Figure 1 ]. He appeared older than his age with loose, pendulous and wrinkled skin over the forehead, cheeks, around the mouth, chest, and other affected sites [ Figure 2a and b].
Laboratory investigations revealed hemoglobin − 10.6 g/dl, leukocytosis (18,300/dl), neutrophilia (N-71%, L-24%, E-3%, M-2%, and B-0.), erythrocyte sedimentation rate was high (40 mm/h), C-reactive protein was negative, and alkaline phosphatase level normal (125 U/L). Serum α1-antitrypsin level was normal 2.14 g/L (0.9-2.0 g/L).
Blood venereal disease research laboratory and human immunodeficiency viruses were negative. Ultrasound abdomen was normal, two-dimensional echocardiography and color Doppler showed normal study. Computed tomography thorax was normal.
Histopathology from wrinkled patch showed unremarkable epidermis, a mild degree of perivascular lymphocytic infiltration, Verhoeff-Von Gieson stain showed a marked reduction in elastic fibres [ Figure 3a ] -features were consistent with cutis laxa.
The section from infiltrated plaque showed mild acanthosis and mild edema, dilated capillaries with plump endothelial cells and diffuse infiltration by neutrophils and few lymphocytes and karyorrhectic debris seen [ Figure 3b ] -suggestive of Sweet's syndrome.
Based on the above clinical findings and laboratory investigations, the diagnosis of acquired cutis laxa type 2 following Sweet's syndrome (Marshall's syndrome) was made.
The patient was started on oral prednisolone 1 mg/kg, the dramatic response was observed in 1-week with rapid clearance of almost all the lesions leaving hyperpigmented atrophic patches over the affected sites. Prednisolone was tapered over a period of 8 weeks without the reappearance of lesions.
DISCUSSION
Sweet's syndrome was first described by Sweet in 1964. [1] Sweet's syndrome is rarely seen in the pediatric population, <80 pediatric cases have been reported in the literature. [2] Fever is the most frequent symptom, skin lesions are typically tender, painful, red or purple-red papules, nodules or plaques seen frequently on upper extremities, face, and neck. The lesions have a transparent vesicle like appearance (pseudo vesicle) because of the pronounced edema in the upper dermis. The central clearing may lead to the annular or arcuate pattern in later stages. The individual lesion may enlarge to form irregular, sharply border plaques. The lesions usually resolve either spontaneously or after treatment without scarring. In two third of patients, it may recur. [3] One of the major diagnostic criteria for Sweet's syndrome is a diffuse infiltrate of mature neutrophils and edema in the upper dermis. Fragmented neutrophil nuclei (karyorrhexis), swollen endothelial cells and dilated small blood vessels may be present. The primary leukocytoclastic vasculitis is absent. [3] Sweet's syndrome can present in several settings; classical, malignancy associated, and drug induced. Sweet's syndrome is often idiopathic. A bacterial infection of upper respiratory tract infection, tonsillitis, or intestinal infection may precede skin lesions by 1-3 weeks. The common malignancies associated with Sweet's syndrome are acute myelogenous leukaemia, carcinoma of genitourinary, breast, or gastrointestinal tract. The drug-induced Sweet's syndrome is seen in granulocyte-colony stimulating factor, cotrimoxazole, and minocycline. [3] Cutis laxa is a rare dermatosis characterized by diffuse laxity of the skin resulting in a prematurely aged appearance.
Cutis laxa can be inherited or acquired condition. Inherited cutis laxa can be autosomal dominant, recessive, or X-linked. Acquired cutis laxa is rare and can be subdivided into type 1 and type 2. Type 1 acquired cutis laxa can be either generalized or localized may occur at any age, though the usual onset is in adulthood, usually follows episodes of inflammatory dermatosis, hypersensitivity reaction to insect bite or drugs such as penicillin, penicillamine, and isoniazide and neoplastic disorders. Systemic involvement is common. [4, 5] Pathogenesis of acquired cutis laxa is unknown, deficiency of α1-antitrypsin may allow protease such as neutrophil elastase to destroy dermal elastic tissues to produce cutis laxa in Marshall's syndrome. [6] Systemic involvement in type 1 is wide and at times severe in the form of pulmonary emphysema, pneumothorax, aortic ectasia, cor pulmonale, inguinal and umbilical hernias, and gastrointestinal and urogenic diverticulae. [4] Marshall's syndrome is characterized by acute inflammatory skin lesions with subsequent development of localized elastolysis without any internal organ involvement. It occurs most often in infancy or childhood. Marshall's syndrome was first described by Marshall et al., in a group of five South African children who had acute erythematous infiltrated papular eruption. [7] A senile aged expression is characteristic and in some cases most of the body surface is involved. [8] There are very few cases reported as Sweet's syndrome leading to acquired cutis laxa -Marshall's syndrome. [9] [10] [11] The systemic steroid is the first line therapy for Sweet's syndrome, as in our patient, showed excellent response with rapid control of progression. There is no satisfactory treatment for cutis laxa.
